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Background: Previous studies on type 2 diabetes have shown an association between exercise capacity and insulin
resistance. In patients with coronary artery disease (CAD) exercise capacity is often reduced due to exercise-induced
ischemia. We have investigated the association between glucometabolic control, including the homeostatic model
assessment (HOMA) of insulin resistance, and exercise capacity in patients with type 2 diabetes and CAD with and
without exercise-induced ischemia.
Methods: In 137 patients (age 63.1 ± 7.9) cardiopulmonary exercise testing on treadmill was performed using a
modified Balke protocol. The highest oxygen uptake (VO2peak) was reported as 30-s average. Fasting blood samples
were drawn for determination of glucose, insulin and HbA1c. Insulin resistance (IR) was assessed by the HOMA2-IR
computer model. Exercise-induced ischemia was defined as angina and/ or ST-depression in ECG ≥ 0.1 mV during
the exercise test.
Results: HOMA2-IR was inversely correlated to VO2peak (r = −0.328, p < 0.001), still significant after adjusting for age,
gender, smoking and BMI. Patients with HOMA2-IR above the median value (1.3) had an adjusted odds ratio of 3.26
(95 % CI 1.35 to 7.83, p = 0.008) for having VO2peak below median (23.8 mL/kg/min). Insulin levels were inversely
correlated to VO2peak (r = −0.245, p = 0.010), also after adjusting for age and gender, but not after additional
adjustment for BMI. The correlation between HOMA2-IR and VO2peak was also significant in the subgroups with
(n = 51) and without exercise-induced ischemia (n = 86), being numerically stronger in the group with ischemia
(r = −0.430, p = 0.003 and r = −0.276, p = 0.014, respectively). Fasting glucose and HbA1c were not correlated with
VO2peak or AT.
Conclusions: Insulin resistance, as estimated by fasting insulin and the HOMA index, was inversely associated
with exercise capacity in patients with type 2 diabetes and CAD, the association being more pronounced in
the subgroup with exercise-induced ischemia. These results indicate that insulin resistance is related to exercise
capacity in type 2 diabetic patients with CAD, possibly even more so in patients with exercise-induced ischemia
compared to those without.
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Exercise capacity is an important prognostic factor in
both healthy and diseased individuals [1-3]. Studies have
shown reduced exercise capacity in patients with type 2
diabetes compared with non-diabetic subjects [4,5]. The
reason for this reduction is not completely understood,
but both cardiac and skeletal muscle dysfunction have
been suggested to play a role in type 2 diabetes [6,7]. In
patients with coronary artery disease (CAD), exercise
capacity is often reduced, primarily because of myocardial
ischemia [8]. Hyperglycaemia is related to both micro-
and macrovascular complications, but there are conflicting
results concerning the association between glucose control
and exercise capacity [9-11]. Insulin resistance, on the
other hand, has been found to be associated with reduced
exercise capacity in patients with type 2 diabetes [11,12].
Because of the increasing prevalence of type 2 diabetes
in the world and the elevated risk for CAD in patients
with type 2 diabetes, there is a growing awareness of
patients suffering both diseases [13,14]. These patients
may have more compromised exercise performance than
patients with either type 2 diabetes or CAD alone, and the
limiting factors of their exercise capacity can be difficult
to determine, especially as silent ischemia is a common
condition in patients with type 2 diabetes and CAD
[15]. Insulin resistance is present in most patients with
type 2 diabetes and is associated with atherosclerosis
[16], but the relationship between insulin resistance and
exercise capacity in patients with both type 2 diabetes and
CAD is not clarified.
The aim of the present study was to investigate the
association between glucometabolic control, including
HOMA index of insulin resistance, and exercise capacity
in patients with type 2 diabetes and CAD with and with-
out exercise-induced ischemia. Our hypothesis was that
insulin resistance was inversely correlated with exercise
capacity in type 2 diabetics with CAD, possibly influenced
by the presence of exercise-induced ischemia.
Methods
Study population
The present study is part of an ongoing randomized,
controlled, clinical trial investigating the effects of exercise
training on progression of atherosclerosis and glucose
control in patients with type 2 diabetes and CAD. Patients
with type 2 diabetes and CAD (n = 137) were included at
the Department of Cardiology, Oslo University Hospital,
Ullevål, Oslo, Norway between August 2010 and March
2012. All study subjects had CAD verified with coronary
angiography and known type 2 diabetes. Exclusion criteria
were presence of severe diabetic complications like prolif-
erative retinopathy and end stage renal disease, cancer,
stroke or acute myocardial infarction within the last three
months, unstable angina, uncompensated heart failure,serious arrhythmia, serious valvular disease, serious rheu-
matologic disease, chronic obstructive pulmonary disease
stadium GOLD IV, thromboembolic disease, ongoing
infections, serious musculoskeletal disorders and other
disabilities seriously limiting the ability for physical
activity. All patients gave informed, written consent to
participate in the study. The study was approved by
The Regional Ethics Committee, was conducted according
to the Declaration of Helsinki and is registered at www.
clinicaltrials.gov, NCT01232608.
Cardiopulmonary exercise test
Established guidelines for exercise testing of cardiac pa-
tients were followed [17]. The cardiopulmonary exercise
test was performed by walking on a treadmill using a
modified Balke protocol [18]. After three minutes of
warm up at 2.8, 3.8 or 4.8 km/hr, the inclination was
increased by 2% each 60s from 4% at start to a maximum
of 20%. If the participant was still able to continue, the
speed then rose by 0.5 km/hr each minute until exhaus-
tion, or ended by the physician for safety reasons. Gas
exchange and ventilatory variables were continuously
measured breath by breath by breathing into a Hans
Rudolph two-way breathing mask (2700 series; Hans
Rudolph Inc, Kansas City, USA). The breathing mask
was connected to a metabolic cart (Vmax SensorMe-
dics, Yorba Linda, USA) to assess the ventilation and
the oxygen and carbon dioxide content of expired air.
The highest oxygen uptake (VO2peak) was reported as
the highest consecutive 30s average of oxygen uptake
during the test. Maximal respiratory exchange ratio
(RER) was registered. The rating of perceived exertion
was obtained using the Borg scale (6–20) [19]. A ca-
pillary blood lactate sample was taken during seated
rest 1–3 min after termination of the exercise test
using haemolysed blood (ABL 700 series, Radiometer,
Copenhagen, Denmark). Heart rate and ST-deviations
were recorded continuously from the 12-lead ECG
record (Cardiosoft, GE Marquette Medical Systems,
Milwaukee, USA). ST-depressions ≥ 0.1 mV 60 ms after
J-point with a ST-slope < 1 mV/s were defined as sig-
nificant. Exercise-induced ischemia in this study was
defined as significant ST-depression and/or develop-
ment of typical angina symptoms during test. The
blood pressure was automated recorded each second
minute of the exercise test, immediately after comple-
tion and after two and four minutes during recovery
(SunTech Tango+ Stress BP, SunTech Medical, Inc.
Morrisville, USA). The anaerobic threshold (AT) was
calculated by the ventilatory equivalent method and
was determined by two independent investigators [8]. In
cases of disagreement, a third investigator was consulted.
If two investigators were not able to determine the AT,
the variable was excluded.
Table 1 Baseline characteristics of the study population
(n = 137)
Characteristics
Age (years) 63.1 ± 7.9
Sex (male/female) 115/ 22
Ethnicity (Caucasian/non-Caucasian) 114/ 23
BMI (kg/m2) 29.2 ± 5.0
Waist circumference (cm) 106 ± 13
Systolic blood pressure (mmHg) 139 ± 17
Diastolic blood pressure (mmHg) 79 ± 9
Metabolic syndrome¤ 105 (77%)
Albuminuria (incl. micro-) 34 (25%)
Current smoker 23 (17%)
Previous myocardial infarction 62 (45%)
Hypertension 100 (73%)
Years of diabetes* 9 (5, 15)
Creatinine (μmol/L)* 79 (68, 91)
LDL (mmol/L)* 2.0 (1.6, 2.6)
HDL (mmol/L)* 1.12 (0.94, 1.38)
Triglycerides (mmol/L)* 1.42 (1.06, 1.91)
HbA1c (%)* 7.4 (6.8, 8.3)
Glucose (mmol/L)* 8.1 (6.9, 9.8)
Insulin (pmol/L)* 57 (33, 102)
C-peptide (pmol/L)* 965 (713, 1290)
HOMA2-IR* 1.3 (0.7, 2.1)
Anti-platelet therapy 129 (94%)
Statin 128 (93%)
Beta-blocker 106 (77%)
ACE-inhibitor/ARB 96 (70%)
Metformin 101 (74%)
Sulfonylurea 47 (34%)
Gliptin 17 (12%)
Insulin/insulin-analogue 26 (19%)
Data presented as proportions or mean value ± SD if not otherwise stated.
ACE; angiotensin converting enzyme. ARB; angiotensin receptor blocker.
*Median (25, 75 percentiles). ¤International Diabetes Federation, 2006.
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Blood samples were drawn by standard venipuncture
between 0800 and 1000 AM after overnight fast and
without medication taken since the preceding evening for
determination of glucose, insulin, c-peptide and HbA1c.
Insulin and c-peptide were measured by Delfia method
(Perkin Elmer) and HbA1c by turbidimetric inhibition
immunoassay (Roche). Glucometabolic control was mea-
sured by fasting serum levels of glucose and insulin, and
fasting blood levels of HbA1c. Insulin resistance was
assessed by the homeostatic model assessment, both
the original HOMA-IR model [20] and the updated
computer model HOMA2-IR [21,22]. Patients on insulin
treatment were included in the calculations as glucose and
insulin were believed to be in a steady state condition at
the time of blood sample collection [23]. All HOMA2-IR
values were calculated by entering glucose and insulin
values in the computer model (not c-peptide). Urine
samples from the same morning were collected for deter-
mination of albumin/creatinine ratio.
Statistical analysis
Demographic data are given as proportions, mean (±SD) or
medians (25, 75 percentiles) with skewed data. Correlation
analyses were performed using Spearman rank test and
trend analysis by Pearson Chi square test. Patients on
insulin treatment were excluded from correlation ana-
lyses between serum insulin and VO2peak/AT. Multiple
linear regression analyses were used to adjust for covari-
ates. Age and gender were considered relevant covariates
in all calculations. Additional covariates were obtained
by investigating differences in baseline characteristics
in dichotomized groups of both dependent and inde-
pendent variables (p < 0.2). Each of the possible covari-
ates was clinically evaluated whether they most likely
represented true confounders or variables related to
the dependent variable through common mechanistic
pathways as the independent variable. In case of the lat-
ter, the variables were not adjusted for. BMI was con-
sidered a confounder, but as adiposity is closely related
to insulin resistance and their associations with exercise
capacity may share common features, multiple regression
analyses were performed both with and without BMI
as part of the relevant covariates. Values of insulin and
HOMA2-IR were log transformed before entered in
the regression models because of skewed data. Logistic
regression was used to calculate odds ratio on dichot-
omized values. Comparisons between ischemic and
non-ischemic groups were calculated by independent
samples T-test, Chi-square test or Mann–Whitney test
as appropriate. Statistical calculations were performed
using SPSS version 18.0. P-value < 0.05 was defined as
statistically significant.Results
Baseline characteristics of the study population are pre-
sented in Table 1, and their physical performances in
Table 2. Fifty-one patients (37%) developed exercise-
induced ischemia during test as defined in this study.
Twelve patients terminated the test because of chest
pain and/or dyspnoea, and the physician terminated three
of the tests for safety reasons (large ST-depressions).
One hundred and twenty-seven patients (93%) reached
RER ≥ 1.10 and/or Borg scale (6–20) ≥ 17 during the
exercise test.
HOMA2-IR was inversely correlated with both VO2peak
and AT (Table 3), and the correlation with VO2peak was
Table 2 Physical performance of the participants in the
total population
Cardiopulmonary exercise test
Exercise time (min:sec) 08:23 ± 02:39
Maximal RER* 1.17 (1.08, 1.23)
Blood lactate (mmol/L)* 6.3 (5.5, 8.4)
Maximal Borg rating scale (6–20)* 17 (17, 19)
Maximal heart rate (beat/ min) 139 ± 19
Maximal systolic blood pressure (mmHg) 188 ± 33
Maximal diastolic blood pressure (mmHg) 82 ± 14
VO2peak (L/min) 2.17 ± 0.56
VO2peak (mL/kg/min) 24.7 ± 5.9
AT (L/min) 1.68 ± 0.42
AT (mL/kg/min) 18.9 ± 4.1
Data presented as proportions or mean value ± SD if not otherwise stated.
RER; respiratory exchange ratio. AT; anaerobic threshold.
*Median (25, 75 percentiles).
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smoking and BMI (Table 4).
Trend analysis through quartiles of HOMA2-IR showed
a significant inverse relationship between increasing
HOMA2-IR and VO2peak (p < 0.001) (Figure 1). Patients
with HOMA2-IR above the median value (1.3) had an
odds ratio of 3.26 (95% CI 1.35 to 7.83, p = 0.008) for
having VO2peak below median (23.8 mL/kg/min) after
adjusting for age, gender, current smoking and BMI.
There were no differences in medication in the quartiles
of HOMA2-IR, except for use of insulin treatment, which
was more frequent in the highest quartile compared with
the three lower quartiles (p < 0.001). Replacing HOMA2-Table 3 Correlation between measures of exercise capacity an
HbA1c(%) Glucose (
VO2peak (mL/kg/min) r = −0.135 r = −0.140
p = 0.117 p = 0.106
AT (mL/kg/min) r = −0.141 r = −0.123
p = 0.144 p = 0.208
$ Patients on insulin treatment excluded. AT; anaerobic threshold.
Table 4 Multiple regression analysis of association between i
logInsulin$
VO2peak (mL/kg/min) β = −0.261a β =
p = 0.005 p =
AT (mL/kg/min) β = −0.277a β =
p = 0.012 p =
VO2peak and AT as dependent variable, and insulin and HOMA2-IR as independent v
current smoking, dage, gender, current smoking and BMI.
$Patients on insulin treatment excluded. β; Standardized beta coefficients.IR with HOMA1-IR did not change the results signifi-
cantly. The levels of significance were, however, overall
marginally stronger with the HOMA2-IR model compared
to the HOMA1-IR model (data not shown).
Insulin levels were inversely correlated with VO2peak
and AT (Table 3), also after adjusting for age and gender,
but not after additional adjustment for BMI (Table 4).
The ischemic and non-ischemic groups did not differ in
baseline characteristics and physical performances, except
for proportions of previous acute myocardial infarction
(AMI) (31% vs 54%, respectively, p = 0.019) and Borg
rating scale (6–20) during the exercise test (17 vs 18,
p = 0.043). The correlation between HOMA2-IR and
VO2peak was statistically significant in both subgroups,
being numerically stronger in the ischemic group
(Table 5). Adjusting for age, gender and current smoking
maintained the statistical significance in both groups,
whereas it disappeared after additional adjustments for
BMI (Table 6).
Glucose control as measured by HbA1c and fasting
glucose did not correlate with VO2peak or AT, neither in
the study population as a whole (Table 3), nor in the
ischemic or non-ischemic subgroups (Table 5).
Discussion
In the present study, our main finding was an inverse
association between estimates of insulin resistance and
exercise capacity in patients with both type 2 diabetes and
CAD. The association was most pronounced between
HOMA2-IR and VO2peak, but present also between
HOMA2-IR and AT, and between insulin and both
VO2peak and AT. Further analysis showed that thed glycemic control/insulin resistance
mmol/L) Insulin$ (pmol/L) HOMA2-IR
r = −0.245 r = −0.328
p = 0.010 p < 0.001
r = −0.225 r = −0.200
p = 0.036 p = 0.048
nsulin resistance and exercise capacity
logHOMA2-IR
−0.111b β = −0.326c β = −0.207d
0.293 p < 0.001 p = 0.027
−0.152b β = −0.278a β = −0.160b
0.233 p = 0.007 p = 0.167
ariable. Adjusted for aage and gender, bage, gender and BMI, cage, gender and
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Figure 1 Peak oxygen uptake in quartiles of HOMA2-IR.
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was present also in the subgroups having ischemia or
not, being numerically stronger in the ischemic group.
Fasting glucose and HbA1c were not correlated with
AT or VO2peak.
After adjusting for BMI, the correlation between
HOMA2-IR and VO2peak was still significant, while the
correlations between HOMA2-IR and AT, and between
insulin and both AT and VO2peak, were not. BMI, as a
measure of adiposity, is of importance when considering
the relationship between insulin resistance and exercise
capacity as body fat may influence insulin resistance and
also maximal oxygen uptake when measured as mL/kg/
min. On the other hand, adiposity and insulin resistance
are part of the metabolic syndrome [24] and may share
patophysiological characteristics, and adjusting for BMI
may result in an underestimation of the relationship
between insulin resistance and exercise capacity. Never-
theless, as HOMA2-IR and VO2peak were still significantly
correlated also after adjusting for BMI, an association
between insulin resistance and exercise capacity inde-
pendent of BMI is indicated in these patients.Table 5 Correlations between VO2peak and glycemic control/ i
(Panel B) (n=86) exercise-induced ischemia
Panel A HbA1c (%) Glucose (
VO2peak (mL/kg/min) r = −0.026 r = −0.059
p = 0.858 p = 0.683
Panel B
VO2peak (mL/kg/min) r = −0.172 r = −0.180
p = 0.116 p = 0.102
$ Patients on insulin treatment excluded.Our main result are in agreement with previous studies
showing inverse association between insulin resistance
and exercise capacity both in healthy subjects, relatives of
patients with type 2 diabetes and in patients with type 2
diabetes [11,25]. There are also indications that treatment
directed against insulin resistance may increase exercise
capacity [26]. In type 2 diabetes, several mechanisms have
been proposed by which insulin resistance and exercise
capacity are related. Associations between insulin resistance
and systolic and diastolic myocardial dysfunction, skeletal
muscle dysfunction, attenuated mitochondrial activity and
endothelial dysfunction have been reported [7,27-29]. All
these pathological conditions can be related to impaired
oxygen uptake and consumption.
The new finding in our study was that the association
between insulin resistance and exercise capacity was also
present in type 2 diabetes patients with CAD, indicating
that insulin resistance may still influence exercise cap-
acity even when myocardial function may be impaired
by the presence of CAD. As exercise-induced ischemia in
patients with CAD may have negative impact on exercise
capacity, it could have been suspected that this associationnsulin resistance with (Panel A) (n=51) and without
mmol/L) Insulin$ (pmol/L) HOMA2-IR
r = −0.339 r = −0.430
p = 0.021 p = 0.003
r = −0.181 r = −0.276
p = 0.155 p = 0.014
Table 6 Multiple regression analyses of association between insulin resistance and exercise capacity in ischemic
(Panel A) and non-ischemic (Panel B) patients
Panel A logInsulin$ logHOMA2-IR
VO2peak (mL/kg/min) β = −0.369
a β = −0.190b β = −0.432a β = −0.315b
p = 0.021 p = 0.325 p = 0.003 p = 0.079
Panel B
VO2peak (mL/kg/min) β = −0.205a β = −0.030b β = −0.289c β = −0.180d
p = 0.075 p = 0.810 p = 0.005 p = 0.101
VO2peak as dependent variable, and insulin and HOMA2-IR as independent variables. Adjusted for
aage and gender, bage, gender and BMI, cage, gender and
current smoking, dage, gender, current smoking and BMI.
$ Patients on insulin treatment excluded.
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ischemia. However, the subgroup analyses in our study
showed a numerically stronger correlation among the
patients with exercise-induced ischemia compared to those
without, indicating that the negative association between
insulin resistance and exercise capacity might be even
stronger in type 2 diabetic patients with exercise-induced
ischemia. These results should be interpreted with caution
and only be considered as hypothesis generating. Neverthe-
less, they may by supported by the theory that insulin
resistance may influence exercise capacity through path-
ways involving endothelial dysfunction and perfusion
disturbances [11]. Insulin resistance is closely related to
endothelial dysfunction [30], and previous studies have
shown that patients with exercise-induced ischemia may
have more severe endothelial dysfunction than patients
without [31]. It can also be speculated that patients with
exercise-induced ischemia are more vulnerable to a certain
degree of endothelial dysfunction in terms of perfusion
disturbances, due to possibly more advanced atheroscler-
otic disease. In both cases, it might be suggested that
the additional impairment of endothelial function caused
by insulin resistance, affects perfusion, and thereby oxygen
uptake, to a greater extent in patients with exercise-
induced ischemia compared to those without.
We realize that the associations presented in the present
study are not suitable for implying any causal relation-
ships, and an alternative explanation to the association
between insulin resistance and exercise capacity may be
that exercise capacity and/or the level of physical activity
have modulating effect on insulin sensitivity. Our study
subjects, with their combination of type 2 diabetes and
CAD, may be habitually sedentary with accompanying low
VO2peak, and this may contribute to insulin resistance.
Physical inactivity has been stated as one of the most
important causes of insulin resistance [32].
We did not find any correlation between glucose control
and exercise capacity. Although some previous studies
have shown an association between glucose control and
exercise capacity [10] and that heart rate and pulmonary
responses to exercise are reduced in type 2 diabetic
patients with poor glucose control [9], our results arein accordance with most studies of type 2 diabetic patients,
showing no association between glucose control and
exercise capacity [5,33]. This indicates that the presence of
CAD in type 2 diabetic patients does not alter these
consistent findings.
Most of the significant correlations in the present
study are in the range of 0.2 to 0.4, implying that only a
minor part of the variance in one parameter is explained
by variations in the other. Nevertheless, VO2peak is a
complex physiological variable being determined by
many different factors, and as it holds important prog-
nostic information, even weaker correlations with this
parameter may be of clinical relevance.Limitations
The hyperinsulinemic euglycemic glucose clamp technique
is the preferred method for measuring insulin resistance
[34], but due to practical reasons, the HOMA model
was used as a surrogate index of insulin resistance in
the present study. This is a well-validated and widely
used method [23], although the model has some short-
comings. The HOMA model gives a surrogate index of
hepatic insulin resistance, and it will not necessarily
reflect peripheral insulin resistance. Further, the method
may not give appropriate results in patients with severely
impaired beta-cell function [34].
Although being an inaccurate measure of overweight,
BMI was used to adjust for adiposity in the correlations
between insulin resistance and exercise capacity. This
may have influenced the results.Conclusions
Insulin resistance, as estimated by fasting insulin and the
HOMA index, was inversely associated with exercise
capacity in our study population of patients with type 2
diabetes and CAD, being more pronounced in the sub-
group with exercise-induced ischemia. These results indi-
cate that insulin resistance is related to exercise capacity
in type 2 diabetic patients with CAD, possibly even more
so in patients with exercise-induced ischemia compared to
those without.
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